Legal & General Group PLC Generation Bio Co. Transaction History

Legal & General Group PLC

$440 Billion
Q2 2024

A detailed history of Legal & General Group PLC transactions in Generation Bio Co. stock. As of the latest transaction made, Legal & General Group PLC holds 3,919 shares of GBIO stock, worth $9,523. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,919

Previous 3,919 -0.0%

Holding current value

$9,523

Previous $15,000 26.67%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$3.65 - $6.9 $3,128 - $5,913	-857 Reduced 17.94%	3,919 $14,000
Q1 2023 May 15, 2023	SELL	$3.61 - $7.01 $56,572 - $109,853	-15,671 Reduced 76.64%	4,776 $20,000
Q4 2022 Feb 14, 2023	BUY	$3.66 - $6.77 $5,409 - $10,006	1,478 Added 7.79%	20,447 $80,000
Q3 2022 Nov 14, 2022	BUY	$4.68 - $8.34 $8,447 - $15,053	1,805 Added 10.52%	18,969 $100,000
Q2 2022 Aug 22, 2022	BUY	$4.87 - $9.41 $2,313 - $4,469	475 Added 2.85%	17,164 $113,000
Q1 2022 May 16, 2022	BUY	$4.16 - $7.76 $694 - $1,295	167 Added 1.01%	16,689 $123,000
Q3 2021 Nov 15, 2021	BUY	$20.0 - $27.43 $141,900 - $194,615	7,095 Added 75.26%	16,522 $414,000
Q2 2021 Aug 12, 2021	BUY	$24.34 - $38.34 $9,030 - $14,224	371 Added 4.1%	9,427 $254,000
Q1 2021 May 17, 2021	BUY	$24.74 - $40.2 $179,043 - $290,927	7,237 Added 397.86%	9,056 $257,000
Q4 2020 Feb 12, 2021	BUY	$21.68 - $51.61 $9,821 - $23,379	453 Added 33.16%	1,819 $52,000
Q3 2020 Nov 13, 2020	SELL	$18.07 - $31.84 $288,632 - $508,580	-15,973 Reduced 92.12%	1,366 $42,000
Q2 2020 Aug 14, 2020	BUY	$20.1 - $24.69 $348,513 - $428,099	17,339 New	17,339 $362,000

Others Institutions Holding GBIO

# of Institutions

Shares Held

50M

Call Options Held

100

Put Options Held

200

View Full List

About Generation Bio Co.

Ticker GBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,011,200
Market Cap $143M
Description
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was f...

More about GBIO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Generation Bio Co. Transaction History